skip to main content

Transcriptomics analysis of synovial fibroblasts by RNA-seq brings new insights into rheumatoid arthritis

Identifiers: SRA: SRP009315
: Rheumatoid Arthritis Synovial Fibroblast RNA Sequencing
Study Type: 
Transcriptome Analysis
Abstract: Rheumatoid arthritis (RA) is a chronic autoimmune-disease of unknown origin that primarily affects the joints and ultimately leads to their destruction. Growing evidence suggests that synvovial fibroblasts play important roles in the initiation and the perpetuation of RA but underlying molecular mechanisms are not fully understood. In the present study, Illumina RNA-seq was used to profile two human normal control and two rheumatoid arthritis synvovial fibroblasts (RASFs) transcriptomes to gain insights into the roles of synvovial fibroblasts in RA. We found that besides known inflammatory and immune responses, other novel dysregulated networks and pathways such as Cell-To-Cell Signaling, Cellular Movement, Cellular Growth and Proliferation, and Cellular Development, may all contribute to the pathogenesis of RA. Our study provided a complete list of those dysregulated genes of both known and novel pathways in RASFs. 5,018 genes were upregulated and 917 genes were downregulated by at least two folds in RASFs vs. controls. Of note, 8,387 known isoforms and 6,826 novel isoforms were upregulated and 2,188 known isoforms and 5,919 novel isoforms were downregulated by at least two folds. The magnitude of difference and the number of differentially expressed known and novel gene isoforms were not detected by DNA microarray before. Since the activation and proliferation of RASFs has been implicated in the pathogenesis of rheumatoid arthritis, further in-depth follow-up analysis of the transcriptional regulation reported in this study may shed light on molecular pathogenic mechanisms underlying synovial fibroblasts in arthritis and provide new leads of potential therapeutic targets.
External Link: /pubmed:23259760

Related SRA data

4 ( 4 samples )
4 (34.0Gbp; 20.6Gb)